XML 23 R10.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s chief operating decision makers (the “CODM function”), which are the Company’s Co-Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, and Chief Operating Officer and Chief Financial Officer, Mr. Soni, utilize consolidated net loss that is reported on the unaudited condensed consolidated statement of operations and comprehensive loss to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company’s consolidated operating budget. The CODM function views the Company's operations and manages its business on a consolidated basis and as a single reportable operating segment. The CODM function is regularly provided with the following significant segment expenses:

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Oncology clinical trial related costs$75,236 $22,980 $179,423 $64,832 
Acquired in-process research and development— — — 15,007 
Compensation related costs, excluding stock-based compensation21,469 12,840 54,123 32,751 
Stock-based compensation130,761 19,371 620,641 39,966 
Other expenses (1)
6,745 3,187 15,312 7,828 
Total segment expenses234,211 58,378 869,499 160,384 
Other income, net2,418 4,578 9,085 8,949 
Interest expense— (2,454)— (8,677)
Net loss$(231,793)$(56,254)$(860,414)$(160,112)


(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.

As of September 30, 2025 and December 31, 2024, substantially all of the Company’s long-lived assets are located in the United States.